Neumora Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Four clinical programs are advancing, with major data readouts for navacaprant in MDD expected in Q2 and promising progress in Alzheimer's agitation, obesity, and muscarinic schizophrenia assets. Regulatory flexibility and robust financials support multiple upcoming catalysts.
-
New phase I-B data for NMRA-511 in Alzheimer's agitation show strong efficacy and safety, with plans for higher dosing and pivotal studies. NMRA-215 is advancing for obesity with a focus on CNS penetration, and key pipeline updates are expected mid-year. Operations are funded into Q3 2027.
-
Phase IB data for NMRA-511 in Alzheimer's agitation showed clinically meaningful reductions in agitation, especially in patients with elevated anxiety, and a favorable safety profile. Plans include higher dose studies, a once-daily formulation, and a Phase II/III trial.
Fiscal Year 2025
-
Significant clinical progress in 2025 included positive NMRA-511 and NMRA-215 data, full enrollment of Navacaprant phase III studies, and advancement of NMRA-898 for schizophrenia. Cash runway extends into Q3 2027, with multiple clinical milestones expected in 2026.
-
Six clinical readouts are expected in the next year across four fully funded programs, including first-in-human studies for a novel NLRP3 inhibitor and advanced trials in Alzheimer's agitation and antipsychotic therapies. Enhanced study designs and operational rigor support a robust neuroscience pipeline.
-
Multiple clinical programs are advancing, including NMRA-215 for obesity, which showed semaglutide-like weight loss in preclinical studies and will enter human trials in 2026. Key Alzheimer’s and MDD studies are also progressing, with several major data readouts expected over the next 12 months.
-
NMRA-215 demonstrated class-leading weight loss and biomarker improvements in preclinical obesity models, with clinical studies planned for 2026. NMRA-511 and Navacaprant are advancing toward key data readouts in Alzheimer's agitation and MDD, respectively, with a strong cash runway supporting multiple upcoming milestones.
-
The event highlighted progress on a CNS-penetrant NLRP3 inhibitor for obesity, with preclinical data due this year and clinical trials planned for 2026. Updates included a dual M4 PAM franchise for neuropsychiatric disorders and operational improvements in ongoing studies.
-
Prioritized obesity as lead indication for NMRA-215, with strong pipeline progress and up to six clinical data readouts expected in the next 18 months. Ended Q2 2025 with $217.6M in cash, supporting operations into 2027 and all key milestones.
-
Q1 2025 saw a net loss of $68M and a cash position of $249.4M, with a new $125M debt facility extending runway into 2027. Key clinical milestones are on track, including NMRA-511 data by year-end and navacaprant Phase III readouts in 2026.
-
A robust neuroscience pipeline is advancing, with seven programs targeting major brain diseases and several clinical catalysts expected this year. Navacaprant's phase III results showed sex-based differences, prompting ongoing analyses and study modifications. Financial strength ensures continued progress and value creation.
Fiscal Year 2024
-
Operating expenses rose year-over-year due to expanded R&D, with a strong cash position supporting operations into mid-2026. Enhanced protocols and site selection are being implemented for ongoing phase three MDD trials after KOASTAL-1's lack of efficacy, while the pipeline advances in Alzheimer's agitation and muscarinic programs.
-
Multiple late-stage trials for novel neuropsychiatric drugs are progressing, with key data from three phase III MDD studies expected by mid-2025. Strong financials support ongoing development, and strategic plans aim for independent commercialization and pipeline expansion.
-
A robust neuroscience pipeline is advancing, led by navacaprant in phase 3 for MDD, with top-line data expected from late 2024 through 2025. The program targets moderate to severe MDD and anhedonia, with strong financial backing and multiple clinical catalysts ahead.
-
Q3 2024 saw increased R&D spending as multiple late-stage clinical programs advanced, with navacaprant's phase III data expected soon. Strong cash reserves support operations into mid-2026, and several clinical catalysts are anticipated over the next 18 months.
-
Navacaprant, a highly selective kappa-opioid receptor antagonist, is advancing through three phase III COASTAL studies for MDD, with top-line data expected in Q4. Phase II results showed robust efficacy and safety, particularly for anhedonia, and the program’s rigorous design aims to maximize regulatory success.